Report of Foreign Issuer (6-k)
September 15 2020 - 7:36AM
Edgar (US Regulatory)
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2020
Commission File Number: 001-38281
ERYTECH Pharma S.A.
(Translation of registrants name into English)
60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON
FORM 6-K
Press Release
On September 14, 2020, the Company issued a press release regarding the hosting of a Key Opinion Leader (KOL) Event to discuss the medical need in
pancreatic cancer and the potential role of eryaspase in this setting. A copy of the press release is attached to this Form 6-K as Exhibit 99.1.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ERYTECH Pharma S.A.
|
|
|
|
|
Date: September 15, 2020
|
|
|
|
By:
|
|
/s/ Eric Soyer
|
|
|
|
|
Name
Title:
|
|
Eric Soyer
Chief Financial Officer and Chief
Operating Officer
|
Erytech Pharma (NASDAQ:ERYP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Erytech Pharma (NASDAQ:ERYP)
Historical Stock Chart
From Apr 2023 to Apr 2024